Allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment that enhances survival and stabilizes neurologic symptoms in X-linked adrenoleukodystrophy (X-ALD) with cerebral involvement, a severe demyelinating disease of childhood. Patients with X-ALD who lack a well-matched HLA donor need a rapid alternative. Haploidentical HSCT using post transplant cyclophosphamide (PT/Cy) has been performed in patients with malignant and nonmalignant diseases showing similar outcomes compared to other alternative sources. We describe the outcomes of transplants performed for nine X-ALD patients using haploidentical donors and PT/Cy. Patients received conditioning regimen with fludarabine 150 mg/m 2 , cyclophosphamide 29 mg/kg and 2 Gy total body irradiation (TBI) with or without antithymocyte globulin. Graft-vs.-host disease prophylaxis consisted of cyclophosphamide 50 mg/kg/day on days +3 and +4, tacrolimus or cyclosporine A and mycophenolate mofetil. One patient had a primary graft failure and was not eligible for a second transplant. Three patients had secondary graft failure and were successfully rescued with second haploidentical transplants. Trying to improve engraftment, conditioning regimen was changed, substituting 2 Gy TBI for 4 Gy total lymphoid irradiation. Eight patients are alive and engrafted (17-37 months after transplant). Haploidentical HSCT with PT/Cy is a feasible alternative for X-ALD patients lacking a suitable matched donor. Graft failure has to be addressed in further studies.
Introduction
X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disease, with an estimated incidence 1:20,000 males [1] . It is caused by a defect in the ABCD1 (ATP binding cassette transporter 1) gene, which is located at Xq28 and encodes for a peroxisomal membrane protein involved in the metabolism of very long chain fatty acids (VLCFAs). These VLCFAs accumulate in the brain and adrenal tissues [2] . There are six distinct clinical phenotypes, including: adrenal insufficiency alone, adrenomyeloneuropathy with or without cerebral disease (CALD), and CALD, of childhood, adolescent, or adult onset [3] . The plasma VLCFA assay is the recommended diagnostic procedure. Characteristic magnetic resonance imaging (MRI) findings are found in patients with the cerebral form of the disease. The childhood-onset cerebral ALD is the most devastating form of the disease; it typically affects young boys from 4 to 8 years of age, presenting initially with behavioral changes and adrenal insufficiency (in most cases), followed by a rapid progressive neurologic deterioration (visual impairment, auditory processing problems, seizures, loss of cognitive, and motor function) leading to death approximately 2-5 years after symptom onset. Approximately 35% of boys with X-ALD will develop CALD [4] [5] [6] . Allogeneic hematopoietic stem cell transplantation (HSCT) may cease the progression of cerebral X-ALD in patients with early stages of disease [7, 8] . The exact mechanism of the HSCT benefit is still not well defined [4, 5] . Early-stage CALD is defined as that in which the patient performs well, has intelligence quotient (IQ) of 80 or higher and less white matter involvement on brain MRI, e.g., Loes score (a 34-point MRI rating scale reported by Loes et al. [9] ) of 9 or less [7] . Prognosis of HSCT in this group is excellent, with mortality rates of <8% reported [10] . Stabilization of the disease usually occurs 6 months after the transplantation [11] . In a study comparing HSCT to the natural history of cerebral X-ALD without treatment, a group of patients with early-stage disease had a 5-year overall survival (OS) estimate of 95% after HSCT, while in the group not receiving transplant, the 5-year OS probability was 54%. Also, the disability status was different between groups: 53% of patients who received transplants and were alive 5 years after the onset of symptoms had a neurologically stable disease, compared with 6% of the nontransplanted group [6] .
Due to the rapid progression of the disease, it is not possible to identify, in a suitable time, an appropriately matched marrow donor, sibling or unrelated, for many patients. In these urgent situations, the use of alternative sources, such as the umbilical cord blood units from unrelated donors and partially mismatched related donors (haploidentical), might be considered [12] [13] [14] .
Historically, the use of alternative sources has been associated with increased incidences of graft-vs.-host disease (GVHD) and graft rejection. Recently, it has been shown by several groups that cyclophosphamide at high doses after HSCT (post transplant cyclophosphamide (PT/ Cy)) can regulate the alloreactivity associated with partially matched donors in pre-clinical [15] and clinical studies [16] . The administration of PT/Cy may selectively deplete the T cells from the alloreactive donor that are responsible for the GVHD, preserving the non-alloreactive, resting memory T cells that can facilitate engraftment and accelerate immune reconstitution [14] [15] [16] [17] . Studies using the nonmyeloablative (NMA) regimen with PT/Cy have shown good outcomes mostly in adults with hematological malignancies, while the experience with children and nonmalignant disorders are scarce [18] [19] [20] [21] .
Here, we hypothesized that NMA transplant with PT/CY using partially matched grafts from related donors (haploidentical) could offer acceptable results for X-ALD patients with indication of an immediate allogeneic HSCT. The objective of this study was to describe a series of cases in which patients with ALD were treated with haploidentical HSCT following NMA conditioning and PT/CY, combining the experience of two institutions, and the effects of this intervention on engraftment, OS, and neurological outcomes.
Materials and methods

Study design, setting and ethics
This is the description of a series of patients with CALD treated in two institutions in Brazil (Hospital of the Federal University of Paraná and Albert Einstein Hospital, through a philanthropic collaboration with the federal Ministry of Health). The study was approved by the institutional review board of both participating institutions. Patients and/or parents signed an institutional review board-approved informed consent forms before HSCT.
Participants: patients and donors
Eligibility criteria for this study included X-ALD diagnosed by VLCFA assay with cerebral involvement showed by characteristic lesions on MRI, good performance status (Karnofsky or Lansky 70-100), ability of parents to sign consent forms, and the presence of a partially (at least haploidentical) HLA-matched relative willing to donate. The patients included had no sibling donor available, and the initial search for matched unrelated donor (MUD) in the national and international donor registries had shown no possibility of a rapidly available well-matched marrow donor.
Donors were screened among first-and second-degree relatives who shared at least one HLA haplotype with the patient and were in good health. HLA typing was done with high-resolution typing (loci A, B, C, DRB1, and DQB1 at allele level) for all patients and donors. Donors were excluded if the patient had donor-specific HLA antibodies detected or if there were other medical reasons. Donor and recipient degree of HLA disparities are described in Table 1 (considering 10 HLA loci-A, B, C, DRB1, and DQB1).
Preparation of donors
Donors received granulocyte colony-stimulating factor (GCSF, 300 μg/day) starting 3 days before marrow harvest. The bone marrow was harvested with a target of >5 × 10 8 nucleated cells/kg of the recipient body weight. There was no graft manipulation except for plasma reduction, and major incompatible ABO grafts had red blood cells depleted by buffy coat preparation. Total nucleated cell doses and CD34+ cell doses are described in Table 1 .
Preparative regimen and GVHD prophylaxis
All patients received fludarabine 30 mg/m 2 on days −6 to −2, and cyclophosphamide 14.5 mg/kg on days −6 and −5. Most patients received total body irradiation (TBI) 2 Gy on day −1, associated or not with rabbit antithymocyte globulin (ATG) 0.5 mg/kg on day −9 and 2 mg/kg on days −8 and −7. Bone marrow was collected and infused on day 0. GVHD prophylaxis was made with cyclophosphamide 50 mg/kg on days +3 and +4 and a calcineurin inhibitor: tacrolimus (to maintain a level of 5-15 ng/dl) or cyclosporine A (to maintain a level of 200-400 ng/dl), together with mycophenolate mofetil (MMF) 15 mg/kg every 8 h, both started on day +5.
Treatment protocol evolution over time
The first patient (Table 1-patient #1) was transplanted after a primary graft failure following a double cord blood transplant. He was rescued with the protocol described above. After this first successful attempt, the same approach was proposed as first-line therapy for other X-ALD patients who needed urgent transplants and had no possibility of suitable related or unrelated donors (voluntary marrow donors or cord blood). For subsequent patients, ATG was added to the classical NMA regimen published by Luznik et al. [16] , aiming to improve engraftment, following the same idea proposed by Bolaños-Meade et al. [19] for sickle cell disease patients published in Blood Journal in 2012. After treating five patients with this approach we still had disappointing results with mixed chimerism and late graft failures. Therefore, in order to try to improve engraftment, the protocol was revised and patient #9 (Table 1) received a different regimen, without ATG and substituting 2 Gy TBI for 4 Gy TLI (total lymphoid irradiation), sparing the brain from radiation.
Supportive care
All patients were hospitalized in reverse isolation with highefficiency particulate air filtration. Patients received bacterial antibiotic prophylaxis with a quinolone, antifungal prophylaxis with micafungin or fluconazol, anti-HSV/VZ prophylaxis with acyclovir and pneumocystis pneumonia prophylaxis with sulfamethoxazole and trimethoprim. Patients were monitored for cytomegalovirus (CMV), Epstein-Barr virus and adenovirus by weekly measurement of viral copy numbers by real-time polymerase chain reaction and preemptive therapy was initiated if threshold number of virus copies was detected. Patients received Time to neutrophil and platelet recovery and GVHD analysis "Time to neutrophil recovery" was defined as the period required to reach at least 500 × 10 3 /mm 3 neutrophils in peripheral blood for three consecutive days. "Time to platelet recovery" was defined as the time to last platelet transfusion to keep platelets counts over 20 × 10 3 /mm 3 . GVHD diagnosis and staging was based on published criteria [22, 23] .
Chimerism analysis
Patients had chimerism measured by short tandem repeat analysis done on total peripheral blood on the day after neutrophil recovery and days +60, +180, and +360. Patients with mixed chimerism (between 5 and 95% donor DNA detected) had studies done monthly to monitor chimerism evolution more closely. Patients with <5% donor chimerism were considered as graft failure.
Neurologic assessment
Patients were administered the Wechsler Intelligence Scale for Children Third Edition or the Wechsler Intelligence Scale for Adults. A Performance Intelligence Quotient below 80 was used as exclusion criteria [24, 25] . The 34-point MRI rating scale devised by Loes et al. [9] was used to grade MRI abnormalities [9] . The Neurologic Function Score (NFS) scale reported by Moser et al. [26] was assessed pre-transplantation and at the most recent followup.
Results
Patient characteristics
From November 2012 to July 2014, nine patients with a confirmed diagnosis of X-ALD were referred to the two participating institutions to be considered for inclusion in this study protocol. All patients had cerebral progressive form of X-ALD with HSCT indication and had at least one HLA-haploidentical related donor. These 9 patients were submitted to 12 HSCT procedures with 11 different HLAhaploidentical related donors ( Table 1 ). The median age at transplant was 7 (range, 6-18 years). They all had adrenal insufficiency at the time of presentation and received lowdose steroids. All patients had neuropsychological evaluation with performance IQ results above 80. The NFS scale reported by Moser et al. [26] was also used to determine neurologic dysfunction severity before and after transplant (the most recent follow-up) and this is reported in Table 1 . Four patients presented with brain MRI with Loes score below 9 (range, 2.5-8), four patients had Loes score between 11 and 12, and one patient had a Loes score of 19. These four cases with more advanced disease classified by MRI (Loes score above 9) were individually and carefully discussed by the HSCT team and families regarding the benefit of the procedure. The entire cohort had very good clinical conditions at the time of transplant. Data are presented as of December 15, 2015.
Donor and graft characteristics
All donors were first-or second-degree relatives (father, n = 7; uncle, n = 2; aunt, n = 1; brother, n = 1) and shared an HLA haplotype with the recipient. The median donor age was 48 years, ranging from 18 to 52 years. All except two grafts (n = 10) consisted of GCSF-primed bone marrow. 
Outcomes
Engraftment and chimerism
The median time to neutrophil recovery over 500 × 10 From the nine patients receiving first haploidentical transplants, eight patients engrafted. Primary graft failure with autologous reconstitution was seen in one patient (patient #3) that recovered blood counts 14 days after transplant with complete recipient chimerism in total blood analysis. This patient with primary graft failure had rapid progression of neurological symptoms and was considered ineligible for a second transplant. Three patients (patient #5, #6, and #7) had secondary graft failure (graft rejection with autologous reconstitution), from 30 days to 12 months after transplant. Patient #6 and #7 were submitted to second transplants with different HLA-haploidentical donors following a preparative regimen with fludarabine 30 mg/m 2 on days −6 to −2, cyclophosphamide 14.5 mg/kg on days −6 and −5, TBI 2 Gy on day −1, and post transplant cyclophosphamide 50 mg/kg on days +3 and +4. Patient #5 had late graft failure and was submitted to a second transplant with the same donor followed by preparative regimen with fludarabine 30 mg/m 2 on days −6 to −2, cyclophosphamide 14.5 mg/kg on days −6 and −5, TLI 4 Gy on day −1, and post transplant cyclophosphamide 50 mg/kg on days +3 and +4.
Graft-vs.-host disease
From eight evaluable patients receiving first haploidentical transplants, two had grade II acute GVHD with good response to treatment with steroids, and two patients had grade III-IV GVHD refractory to steroids that needed further immunosuppression (extracorporeal photopheresis, mesenchymal stem cells, sirolimus). One patient (#2) had good response to second-line treatment and resolved GVHD; the other (patient #4) had associated gastrointestinal adenovirus infection and died 8 months post transplantation with bacterial sepsis and progressive neurological disease.
Transplant-related complications and infections
All patients developed mild or moderate signs of mucositis, no patient had sinusoidal obstruction syndrome, and 1 patient developed hemorrhagic cystitis associated with BK virus infection. From the nine patients receiving first haploidentical transplants, five had fever and inflammatory symptoms in the days following graft infusion, which ceased with PT/Cy administration. Two of three patients receiving two haploidentical transplantations also developed inflammatory symptoms after the second transplant procedure.
Four patients developed CMV reactivation treated successfully with ganciclovir or foscarnet. One of them had severe CMV-related pneumonitis. Two patients had respiratory infections (syncytial respiratory virus and parainfluenza) with mild symptoms. One patient (patient #4) had severe adenovirus infection with gastrointestinal involvement and one patient had poliomavirus-(BK virus) associated cystitis.
Survival and neurological outcomes
All patients except a few were alive at a median of 29 months (range, 17-37 months). Patient #4 died from severe GVHD and adenovirus infection and had a rapid and severe neurological progressive disease. Patient #3 had autologous reconstitution associated with rapid neurologic disease progression and is currently alive but in poor neurological condition. Patient #8 is alive and is currently being evaluated for a late graft rejection (29% donor chimerism) and a second transplant with a different donor is in consideration. Until the latest follow-up, he presented with no signs of neurological disease progression, and his brain MRI remains stable. The remaining six patients are alive and engrafted. At the time of last visit, patient #1 had stable neurological disease (only mild symptoms with hyperactivity and attention deficit) and he goes to school with good performance. Patient #2, #5, #6, and #9 are alive and have complete donor engraftment, but had initial neurologic disease progression with stabilization of symptoms around 12 months after transplant. They receive supportive and rehabilitation care (motor skills, visual adaptation) at home. Patient #7 is alive and engrafted but has progressive neurological disease. Patients' NFS at the most recent follow-up are described in Table 1 .
Discussion
Allogeneic HSCT is still the only treatment that was shown to halt the severe and progressive symptoms of cerebral X-ALD. Excellent results are achieved when HSCT is performed in the early phase of the disease and these patients should be referred to a transplant center as soon as possible [3, 10, 11, 27] .
Finding a suitable matched donor in a timely manner is a challenge. Particularly in populations with a major degree of miscegenation, like our country's population, this search may take as long as 6 to 12 months. In a study performed by the National Registry of Donors, the median time to find an MUD was 85 days (personal communication). For this reason, the use of alternative donors may be considered early in the treatment of X-ALD patients.
Historically the use of mismatched related donors (haploidentical) is associated with severe GVHD. Removing mature cytotoxic T-cell lymphocytes from the graft (e.g. CD34+ cell selection) has resolved this prohibitive GVHD, but increased the incidence of graft failure and infections due to delayed immune reconstitution. In addition, current techniques of T-cell depletion are expensive and not easily available in low-income countries. By using post transplant cyclophosphamide, several groups have reduced GVHD incidence significantly after haploidentical HSCT for malignant diseases, reaching levels similar to HSCT from a related sibling donor [16] [17] [18] . Because of these results and the immediate availability of haploidentical donors, we proposed a protocol using this technique for X-ALD patients with urgent indication of HSCT. All nine patients included in our study had CALD with HSCT indication, no sibling donor available, and the initial search for MUD in the national and international donor registries had shown no possibility of a rapidly available well-matched marrow donor.
Unlike patients with malignant diseases, patients with X-ALD have never received chemotherapy or other immunosuppressants before HSCT with the exception of low-dose steroids for adrenal insufficiency. Thus, they may have higher probability of failure of engraftment when compared to patients with already damaged immune responses. For this reason, we decided to increase immunosuppression by adding ATG to the classic NMA regimen following the idea used already in patients with hemoglobinopathies by Bolaños-Meade et al. [19] . In addition, we tried to increase CD34+ cell concentration in grafts using GCSF in donors prior to marrow collection. Regardless of these modifications, among our seven first treated patients, one had primary graft failure and four had progressive graft failure after initial engraftment. Three of them received a successful second haploidentical transplant. At this moment, we decided to augment immunosuppression by increasing irradiation dose. Instead of using 2 Gy TBI, we proposed to use 4 Gy TLI, trying to spare brain from irradiation. With this new regimen we treated two patients; both of them reached stable full donor chimerism. Other alternatives could be proposed aiming to optimize immunossupression and prevent autologous reconstitution, including: changing ATG doses and schedule, increasing dose of irradiation or including more myeloablative drugs in the regimen.
The high incidence of graft failure may have been due to the use of an NMA conditioning regimen. In our study this was initially proposed because patients had already advanced neurologic disease. Even after the decision to improve immunossupression with higher radiation doses, we tried to avoid brain irradiation in order to minimize neurotoxicity to these patients already with advanced cerebral disease. This decision may also have to be reviewed since there are studies (mainly pre-clinical studies in other similar diseases) that show that donor-derived microglial engraftment is associated with better neurological outcomes, and that better microglial engraftment is achieved with myeloablative regimens with CNS penetrating drugs or radiation [28, 29] .
Although it is well known that transplants have to be performed early after CALD diagnosis, patients in our protocol were referred with already significant progression of symptoms and MRI abnormalities. Among the nine patients transplanted, four of them had stable engraftment of donor cells. From these, only one patient (patient #1) remained with stable neurologic disease after HSCT. The other three patients, despite engraftment, had worsening of symptoms and MRI abnormalities early after HSCT. One patient died of transplant-related complications and the other two patients are alive, having had neurologic symptoms stabilized around 1 year after transplant. Three patients had progressive graft failure (with autologous reconstitution) and were submitted to a second transplant; all of them had signs of disease progression between the two transplants. One of them stabilized symptoms after the second HSCT; the remaining two patients are alive with progressive disease. The demyelination process in patients with CALD is associated with a strong inflammatory reaction in the CNS white matter, with perivascular infiltration with CD8 cytotoxic T lymphocytes leading to cytolysis of oligodendrocytes. It has been reported that inflammatory reactions like acute GVHD can be associated with rapid clinical deterioration in X-ALD patients [3, 6, 27] .
In the scenario of haploidentical transplantation using PT/Cy as GVHD prophylaxis, several groups reported the occurrence of noninfectious fever between day 0 and day 5 after graft infusion. It was hypothesized that this finding could be related to a cytokine release from proliferating alloreactive T cells [30] . In 6 of the 12 transplant procedures in our study, patients had fever episodes between day 0 and day +5, and four of them presented fever later on, with the occurrence of grades II-III acute GVHD. We could then speculate that these inflammatory reactions could also have influenced in the progression of the demyelination process. This association, however, has to be studied more carefully and in larger cohorts.
In conclusion, we have shown that haploidentical HSCT with post transplant cyclophosphamide is a feasible alternative for patients with CALD lacking a well-matched HLA donor, but graft rejection is still an issue when using NMA conditioning regimen. Optimal conditioning regimen to prevent graft rejection (increasing intensity) and support therapy aiming to reduce inflammatory reaction after cell infusion are still points that need to be better addressed in larger patient cohorts.
